PSA 0.6 ng/mL: Interpretation and Follow-Up
A PSA of 0.6 ng/mL is normal and requires no immediate intervention; continue routine screening every 2–4 years if the patient is between 45–75 years old with >10 years life expectancy.
Risk Assessment
A PSA of 0.6 ng/mL falls well below the traditional 4.0 ng/mL threshold and represents a very low probability of prostate cancer—approximately 6.6–10.1% based on population studies. 1
Men with PSA ≤1.0 ng/mL have only a 0.5% risk of metastatic disease by age 85 and a 0.2% risk of death from prostate cancer, indicating excellent long-term prognosis. 2
The median PSA for men in their 40s is 0.7 ng/mL and 0.9 ng/mL for men in their 50s, placing a value of 0.6 ng/mL at or below the median for younger age groups. 2, 1
Recommended Screening Interval
For PSA <1.0 ng/mL, repeat testing every 2–4 years is appropriate in men aged 45–75 years. 2
Younger men (e.g., 45 years old) with PSA on the higher end of this range (0.9 ng/mL) should be screened in 2 years, whereas older men with lower PSA (e.g., 0.6 ng/mL at age 60) can safely extend the interval to 4 years. 2
Men with PSA <1.0 ng/mL at 4-year intervals had only a 0.23% cancer risk at 4 years and 0.49% at 8 years in the Rotterdam ERSPC trial, supporting extended screening intervals. 2
When to Discontinue Screening
PSA testing should only be offered to men with ≥10 years life expectancy, regardless of chronologic age. 2
For men ≥70 years, screening benefits are uncertain; most randomized trials showed benefit only up to age 70, and any survival advantage would not appear until 9–10 years after testing. 2, 3
In men ≥80 years, discontinue PSA screening entirely unless obstructive urinary symptoms develop, as overdiagnosis rates reach 23–42% and most screen-detected cancers remain clinically silent. 3
What Does NOT Require Action at PSA 0.6 ng/mL
No biopsy is indicated at this PSA level in the absence of an abnormal digital rectal examination (DRE). 2, 1
PSA velocity calculations are not useful at this low baseline; velocity thresholds (≥0.35 ng/mL/year for PSA <4.0 ng/mL) apply only when serial measurements show sustained rises. 1
Free PSA ratio testing is unnecessary because the total PSA is far below the 4–10 ng/mL "gray zone" where free PSA helps differentiate benign from malignant disease. 1
Critical Clinical Pitfalls
Do not omit DRE at any PSA level; a palpable nodule, asymmetry, or induration is an absolute indication for biopsy regardless of PSA value. 2, 1
Do not screen men with <10 years life expectancy or severe comorbidities, as the harms of overdiagnosis and overtreatment outweigh any potential benefit. 2, 3
Do not use age alone to determine screening eligibility; functional status and comorbidities are more important than chronologic age in men <75 years. 2
Do not forget to adjust PSA values if the patient is on a 5α-reductase inhibitor (finasteride or dutasteride); these agents lower PSA by approximately 50%, so the measured value should be doubled. 4, 1
Special Populations
Men on Testosterone Replacement Therapy
Obtain baseline PSA and DRE before initiating testosterone; if baseline PSA >4.0 ng/mL or DRE is abnormal, perform biopsy before starting therapy. 4
During testosterone therapy, perform biopsy if PSA rises >1.0 ng/mL in any calendar year; for rises of 0.7–0.9 ng/mL, repeat PSA in 3–6 months and biopsy if elevation persists. 4
High-Risk Populations
African-American men and those with first-degree family history of early-onset prostate cancer should begin screening at age 40–45 years, but the same PSA thresholds and intervals apply. 2
At PSA 0.6 ng/mL, even high-risk men do not require more frequent screening than the standard 2–4 year interval for PSA <1.0 ng/mL. 2
Summary Algorithm
| PSA Level | Age | Life Expectancy | Recommended Action |
|---|---|---|---|
| 0.6 ng/mL | 45–75 yr | >10 yr | Repeat PSA in 2–4 years; perform DRE |
| 0.6 ng/mL | ≥75 yr | >10 yr | Individualize; consider stopping screening |
| 0.6 ng/mL | Any age | <10 yr | Discontinue screening |
| 0.6 ng/mL | Any age | Abnormal DRE | Proceed to biopsy regardless of PSA |